Legend Biotech Corporation reported impressive fourth-quarter results, with CARVYKTI net trade sales reaching $555 million, marking a 66% year-over-year increase. The company’s total revenue for the quarter was $306 million, reflecting a robust 64% growth, significantly outpacing operating expenses, which grew only 6%. The firm also highlighted a substantial reduction in operating losses, down 75% from the previous year, and achieved profitability for the CARVYKTI franchise in 2025, with expectations for company-wide profitability by 2026.
These results underscore Legend Biotech’s strong market position in the CAR-T therapy landscape, particularly for multiple myeloma, as CARVYKTI is increasingly utilized in earlier treatment lines. The company has expanded its manufacturing capacity to support 10,000 annual doses and plans to scale this to 20,000, enhancing its ability to meet growing demand. Furthermore, the partnership with Johnson & Johnson aims for peak annual sales exceeding $5 billion, reinforcing the company’s growth trajectory.
Market professionals should note the strong momentum in CARVYKTI’s adoption and the anticipated profitability, which positions Legend Biotech favorably for sustained growth and potential market share expansion in the competitive CAR-T therapy sector.
Source: fool.com